Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels
2008

Effects of a Genetic Variation in the PSA Gene on Prostate Cancer Risk

Sample size: 1176 publication Evidence: high

Author Information

Author(s): Jesser C, Mucci L, Farmer D, Moon C, Li H, Gaziano J M, Stampfer M, Ma J, Kantoff P

Primary Institution: Harvard School of Public Health

Hypothesis

Does the G/A polymorphism in the PSA gene affect prostate cancer risk and survival?

Conclusion

The study found no significant association between the rs266882 polymorphism in the PSA gene and prostate cancer risk or survival.

Supporting Evidence

  • The study included a large sample size of 500 cases and 676 controls.
  • Conditional logistic regression was used to analyze the data.
  • No significant associations were found between the rs266882 genotype and prostate cancer risk.
  • Meta-analysis of 12 studies also showed no overall effect of the variant on prostate cancer risk.

Takeaway

This study looked at a specific gene change to see if it affects prostate cancer risk, but it found that it doesn't seem to make a difference.

Methodology

A nested case-control study was conducted with 500 prostate cancer cases and 676 matched controls, analyzing genetic data and PSA levels.

Potential Biases

Potential for population stratification due to the focus on a specific ethnic group.

Limitations

The study was limited to white men, which may affect the generalizability of the findings.

Participant Demographics

500 white male prostate cancer cases and 676 matched controls, aged 40-84.

Statistical Information

Confidence Interval

95% CI: 0.88–1.67 for risk, 95% CI: 0.56–1.58 for survival

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604690

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication